Meeting
2011 ASCO Annual Meeting
Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.
Authors
D. Malka
Institut Gustave Roussy, Villejuif, France
D. Malka , S. Gourgou-Bourgade , J. Emile , P. Laurent-Puig , J. Taïeb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Esophageal, Gastric, or Small Bowel
Clinical Trial Registration Number
2009-012797-12
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS178)
Abstract #
TPS178
Poster Bd #
45H
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).
First Author: David Malka
Poster
2021 ASCO Annual Meeting
A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).
First Author: MinKe He
Poster
2018 Gastrointestinal Cancers Symposium
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
First Author: Haeseong Park
Poster
2015 Gastrointestinal Cancers Symposium
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
First Author: Francesco Leone